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Severe restless legs syndrome in a family
with Alport syndrome
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Abstract
Background: Restless legs syndrome (RLS) is a common sleep-related movement disorder characterized by an urge
to move the legs during inactivity, especially at evening-night. RLS is highly prevalent in patients with kidney failure
and have an impact on quality of life, mood, sleep quality and overall on compliance to the dialysis. Alport
syndrome (AS) is a rare inherited disease, predominantly X-linked, secondary to mutations in genes encoding α3, α4
or α5 chains of type IV collagen, and characterized by hematuria, chronic kidney disease, neurosensory deafness,
and lenticonus.
Case presentation: Here we describe a family with a combination of X-linked AS and severe RLS accompanied by
periodic limb movements during sleep (PLMS). In the first patient we identified, RLS was complicated by a
paradoxical response to dopamine agonists named “augmentation”, leading to sleep disruption, hallucinations and
five peritoneal perforations during the peritoneal dialysis due to the difficulty to rest still. Therapeutic adjustments
and renal transplantation improved RLS and PLMS. In two brothers, severe RLS prevented a compliance with
hemodialysis. Female family members carrying the mutation were also affected by RLS, while those without the
mutations were RLS-free.
Conclusions: RLS has not been reported earlier in association with AS, but the peculiar combinations observed in
this family will stimulate further clinical studies and motivate nephrologists to seek for RLS symptoms and sleep
disturbances in AS patients.
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Background
Alport syndrome (AS) is a rare genetic disorder, pre-
dominantly X-linked, with mutations in the genes en-
coding α3, α4, or α5 chains of collagen IV (COL4A3,
COL4A4, and COL4A5) [1]. Since type IV collagen is
expressed in several tissues, AS is a multi-organ disease
characterized by hematuria, progressive chronic kidney
disease (CKD), neuro-sensorial deafness, and lenticonus.
In the most common X-linked form, females carrying
the mutation are usually asymptomatic, while males in-
herit the disease from mothers and develop symptoms
with high penetrance with CKD progressing to kidney
failure often before the age of 40 years [2].
Restless legs syndrome (RLS) is a common sleep-
related sensory-motor disorder, affecting approximately
5 % of the general population in adults, with a female
preponderance [3]. RLS is characterized by an uncom-
fortable urge to move the legs emerging or worsening at
rest, mainly at evening/night, which improves or disap-
pears with movement [4]. In moderate-severe cases, RLS
impacts sleep, mood, cognition and, in general, quality
of life, being as stressful as chronic diseases like diabetes
and rheumatoid arthritis [5]. In around 90 % of patients,
RLS is accompanied by periodic limb movements during
sleep (PLMS) which contribute to sleep fragmentation
and in the long-term may increase the risk of
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cardiovascular disease. RLS can be classified as primary/
idiopathic, or secondary/symptomatic if associated to
pathological conditions such as iron deficiency, [6] preg-
nancy, [7] some neurological disorders, [8] and CKD [9].
The prevalence of RLS in CKD exceeds rates of 20–
25 %, with a very high prevalence in patients with kidney
failure and on dialysis (28.4 %) and a partial resolution
after kidney transplantation (6.7 %). RLS is associated
with an adverse prognosis and higher mortality in CKD
[10]. Compared to RLS free counterparts, hemodialysis
patients with RLS are subjects of increased muscle atro-
phy [11], depression, anxiety, sexual dysfunction, further
reduction in quality of life and sleep quality [12–14]. Be-
cause of the legs discomfort during periods of inactivity,
patients with RLS are twice as likely to leave dialysis
early [15]. Dopamine agonists, such as pramipexole,
ropinirole and rotigotine, are first line treatments for
RLS, which are initially well tolerated and highly effect-
ive, even at low dosages and from the first night of
administration.
In this paper, we report, for the first time, the associ-
ation between RLS and AS in a large family, also focus-
ing on the diagnostic, therapeutic and
pathophysiological aspects.
Case presentation
A 65-year-old man affected by AS presented at the
emergency room for psycho-motor agitation and halluci-
nations, acutely emerged after a severe chronic sleep
deprivation, without any previous psychiatric history. He
was also affected by RLS since the age of 10 years and,
at time of our visit, was treated with pramipexole
0.75 mg/day. He had hearing but not major visual im-
pairment and has been on peritoneal and then on
hemodialysis for 1 year. A previous skin biopsy had re-
vealed an abnormal distribution of the alpha chain of
type IV collagen with the absence of the alpha 5 chain.
The genetic test showed an X-linked (hemizygote) mis-
sense mutation of COL4A5 gene (c.3319 G > A; p.
G1107R). The genetic analysis was extended to the other
family members. His 83-year-old mother, as well as his
daughter, two sisters, a niece, and two dead brothers suf-
fered of RLS and presented the same AS mutation
(Fig. 1). All the female members in the family carrying
the AS mutation presented proteinuria and hematuria,
with normal creatine clearance. The patient reported
that his two brothers died because they were unable to
undergo hemodialysis because of their severe RLS, which
did not allow them to stay still long enough to carry out
dialysis sessions. The patient had suffered peritoneal per-
foration for five times because of his need to move and
inability to stay still during peritoneal dialysis; this led to
the decision to shift to hemodialysis.
A video-polysomnography (v-PSG) one year before
our evaluation and under treatment with pramipexole
0.5 mg/day at 9 pm, showed disrupted sleep with sleep
efficiency of 64 % and a PLMS index (number of PLMS
per hour of sleep) of 72/hour (very severe, pathological
threshold > 15/hour) (Fig. 2). Serum ferritin, transferrin
saturation, vitamin D, folate and vitamin B12 were nor-
mal. During the last week preceding our evaluation, he
had presented an unusual aggressive behaviour and, for
Fig. 1 Patient’s family tree. The grey background indicates subjects affected by RLS. AS, male subjects with Alport syndrome. CM, female subjects
carrying the mutation. The asterisk identifies the proband. Bars across squares indicate deceased subjects
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the first time, he had refused his regular nephrological
check-up. RLS symptoms were very severe (IRLS Rating
Scale score 34, range 0–40). A clear augmentation
phenomenon was diagnosed, based on the intensification
of symptoms during the day, an extension of them to
the upper limbs and trunk, with impossibility to rest and
failed attempts to increase the dosage of pramipexole.
His wife reported that the patient had several sleep at-
tacks during the day, with one of them occurring during
walking and causing a fall and a zygomatic bone
fracture.
A fourteen-day actigraphic recording showed a
complete sleep disruption in the first week of recording
(Fig. 3b). Following a modification of the treatment
protocol, from pramipexole 0.75 mg/day at 9 pm to pro-
longed release pramipexole 0.75 mg plus clonazepam
0.5 mg, at bedtime, strongly improved his sleep-wake
pattern. The improvement was documented by actigra-
phy in the second week of recording (Fig. 3c). The IRLS
Rating Scale score decreased to 22.
One year later, the patient underwent kidney trans-
plantation. During the procedure, the RLS therapy
was acutely withdrawn, with the appearance of a se-
vere state of motor agitation that almost compro-
mised the surgical outcome and needed opioids in
addition to the previous therapy to be controlled.
Two months after transplantation, RLS symptoms
considerably improved (IRLS Rating Scale score 4),
and then remained stable.
A v-PSG performed 5 years after transplantation
showed a normal sleep efficiency and the disappearance
of PLMS. The last clinical follow-up, performed 8 years
after transplantation showed a good control of symp-
toms obtained with pramipexole extended release
0.375 mg/day at 4 pm, rotigotine transdermal patch
3 mg/day and clonazepam 0.5 mg/day.
Discussion and conclusions
To the best of our knowledge, this is the first observa-
tion of RLS in AS. Sleep disorders in general do not
seem to be mentioned in the literature regarding the
clinical picture of AS. In the present case, RLS was par-
ticularly severe, leading to a profound sleep disruption,
with a major impact on the patient’s quality of life and
potentially affecting the outcome of transplantation and
dialysis. The development of augmentation represented
an additional aggravating factor in management of RLS
symptoms.
It is known that, in the long term, RLS patients treated
with dopamine agonists may develop a severe drug-
related complication named “augmentation”, character-
ized by a paradoxical response to an increase of drug
dosage, a worsening and spreading of symptoms to body
parts other than legs and to other periods of the day and
not only at evening/night. After an average of 3 years,
approximately 20 % of RLS patients develop augmenta-
tion during treatment with dopamine agonists. Augmen-
tation represents a real challenge for sleep specialists,
Fig. 2 Five minutes polysomnographic sample of NREM sleep showing a sequence of periodic limb movements during sleep (grey background),
recorded by surface electromyography of both left and right tibialis anterior muscles (LTA, RTA). Cortical arousals coupled with motor events
visible at electroencephalic channels. F3 and F4 frontal left and right; C3 and C4 central left and right; O2 occipital right; A1 and A2 mastoid left
and right; EOG = electrooculogram; Chin = electromyography of submentalis muscle; EKG = electrocardiogram; ONF = oro-nasal flow; TM = thoracic
movements; AM = abdominal movements
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who often have to fall back to opioids to treat their pa-
tients [16].
The shift from an immediate to an extended-release
formulation of pramipexole drastically ameliorated RLS,
as already reported in augmented idiopathic RLS [17],
while transplantation further improved and stabilized
symptoms. Alternative treatments to avoid augmentation
in ESRD patients are represented by alpha-2-delta li-
gands compounds, like gabapentin or pregabalin [18], as
well as by non-pharmacological interventions including
repetitive transcranial magnetic stimulation, compres-
sion devices, infrared therapy [19]. Of note, in a random-
ized placebo controlled trial, a 6-month exercise training
regime was as effective as a low dosage dopamine agon-
ist treatment in reducing RLS symptoms in hemodialysis
patients [20]. Aerobic exercise training additionally im-
proves quality of life, depression and physical perform-
ance in uremic patients [21, 22].
This case clearly shows that RLS can significantly im-
pact and complicate the treatment of patients with AS,
also increasing by far the nursing workload during
hemodialysis sessions. There are at least three
speculative considerations on the possible causal rela-
tionship between these two conditions that deserve to be
discussed.
First, the occurrence of RLS in five females, heterozy-
gous carriers of the AS genetic trait but with preserved
renal function, seems to exclude the possibility that RLS
is dependent only on renal failure in this family. How-
ever, we should take into consideration that although
apparently healthy, the women with the AS mutation in
our family might have been affected by a minimal kidney
involvement, expressed by proteinuria and hematuria; in
fact, it has been reported that females carriers of a mis-
sense mutation of the AS gene (as in our family) have a
higher risk to have proteinuria than those with non-
missense mutations [23]. In any case, CKD might have
exacerbated RLS, explaining its higher severity in the
male family members. Second, all members affected by
AS or carrying the mutation were also affected by RLS.
Therefore, we cannot exclude that the AS genetic muta-
tion might be responsible also for RLS through an un-
known mechanism. Despite being theoretically possible,
this hypothesis does not seem to be supported by
Fig. 3 (a) Average actigraphic motor activity before (black area) and after (white area) drug management. (b) One-week actigraphic recording
during treatment with immediate release pramipexole 0.75 mg/day, showing severe insomnia and high levels of motor activity during daytime.
(c) One-week actigraphic recording after therapeutic shifting to pramipexole 0.75 mg plus clonazepam 0.5 mg, at bedtime, showing a significant
improvement of both night sleep and a motor activity during daytime
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genetic studies conducted so far in RLS. The AS muta-
tion is not included among the allelic variants signifi-
cantly associated with RLS by genome wide analyses, nor
among those found by linkage studies in familial RLS
[24]. Moreover, in idiopathic familial RLS, symptoms are
typically inherited with autosomal dominant modality
and are prevalent in women. A third possibility is that
the association between RLS and AS was simply inciden-
tal and a feature of this family only. Further families and
patients with AS need to be screened for RLS in order to
attempt to address the latter two hypotheses.
Finally, we recommend nephrologists to always care-
fully seek for RLS symptoms in patients with AS, be-
cause RLS is a condition that deeply affects quality of
life, sleep and compliance to the dialysis. These patients
need a multidisciplinary approach for an appropriate
therapeutic intervention, and transplantation should be
accelerated in the case of comorbidity with RLS.
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